Inclusion Criteria:

Histologically or cytologically documented malignancy that is now advanced and/or
metastatic and refractory to established forms of therapy or for which no effective
therapy exists.

Age >/= 18 years, ECOG PS 0-2, life expectancy >/= 12 weeks Prior chemotherapy is
permitted provided that a minimum of 3 weeks has elapsed. Prior tyrosine kinase inhibitor
therapy is permitted. Patients must have recovered from any treatment-related toxicities
(with some exceptions) prior to registration.

Prior hormonal therapy is permitted provided it is discontinued prior to registration
(with the exception of prostate cancer patients who have been on hormone therapy for at
least 3 months).

Prior radiation therapy is permitted provided that it did not exceed 25% of bone marrow
reserve and patients have recovered from the toxic effects. A minimum of 21 days must
have elapsed unless the radiotherapy was palliative and nonmyelosuppressive.

ANC >/= 1.5 x 10^9/L, PLT >/= 100 x 10^9/L; bilirubin (ULN), AST and ALT follow-up. Patients must practice effective contraceptive measures throughout the study.
Provide written informed consent.

Exclusion Criteria:

Symptomatic brain metastases which are not stable, require steroids, are potentially
life-threatening or that have required radiation within the last 28 days.

History of allergic reaction attributed to a similar compound as study drug. Significant
cardiac disease unless well controlled, poorly controlled hypertension.

Active or uncontrolled infections of serious illnesses or medical conditions that could
interfere with participation.

History of any psychiatric condition that might impair the patient's ability to provide
informed consent or participate.

Concurrent anticancer therapy. Use of CYP3A4 inducers/inhibitors during the 14 days prior
to first dose. Pregnant or breast-feeding females.